| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.04 | 0.6 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.042 | 0.6 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |